(Q48262695)

English

Inhibition of cerebral type 1 cannabinoid receptors is associated with impaired auditory mismatch negativity generation in the ketamine model of schizophrenia.

scientific article published on 18 May 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/21590281

Inhibition of cerebral type 1 cannabinoid receptors is associated with impaired auditory mismatch negativity generation in the ketamine model of schizophrenia. (English)

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/21590281

0 references

0 references

0 references

cannabinoid receptor

0 references

Ida S Haussleiter

object named as

Ida S Haussleiter

2

0 references

7

object named as

Georg Juckel

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/21590281

author name string

Patrik Roser

1

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/21590281

Hee-Jeong Chong

3

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/21590281

Christoph Maier

4

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/21590281

Wolfram Kawohl

5

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/21590281

Christine Norra

6

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/21590281

publication date

18 May 2011

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/21590281

number of pages

10

1 reference

based on heuristic

inferred from page(s)

Psychopharmacology

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/21590281

218

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/21590281

4

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/21590281

611-620

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/21590281

https://scigraph.springernature.com/pub.10.1007/s00213-011-2352-y

0 references

Cannabinoid receptor antagonists counteract sensorimotor gating deficits in the phencyclidine model of psychosis.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Cannabinoids and psychosis

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Isolation and structure of a brain constituent that binds to the cannabinoid receptor

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Pharmacological models in healthy volunteers: their use in the clinical development of psychotropic drugs

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Testing the glutamate hypothesis of schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

The interplay of cannabinoid and NMDA glutamate receptor systems in humans: preliminary evidence of interactive effects of cannabidiol and ketamine in healthy human subjects

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Mismatch negativity generation in the human 5HT2A agonist and NMDA antagonist model of psychosis.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Cannabinoid receptor localization in brain

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Role of cortical N-methyl-D-aspartate receptors in auditory sensory memory and mismatch negativity generation: implications for schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Acute effects of Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory evoked mismatch negativity

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Stimulation of endocannabinoid formation in brain slice cultures through activation of group I metabotropic glutamate receptors.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Effects of haloperidol on selective attention: a combined whole-head MEG and high-resolution EEG study

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Dopamine modulates involuntary attention shifting and reorienting: an electromagnetic study

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors-implications for models of schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Molecular composition of the endocannabinoid system at glutamatergic synapses.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Cannabinoids inhibit the release of [3H]glutamate from rodent hippocampal synaptosomes via a novel CB1 receptor-independent action

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: a combined immunochemical and pharmacological analysis.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

The effect of methylphenidate on auditory information processing in healthy volunteers: a combined EEG/MEG study

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Effect of ketamine on the neuromagnetic mismatch field in healthy humans.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Acute dopamine D(1) and D(2) receptor stimulation does not modulate mismatch negativity (MMN) in healthy human subjects.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Acute dopamine and/or serotonin depletion does not modulate mismatch negativity (MMN) in healthy human participants

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Cognitive consequences of cannabis use: comparison with abuse of stimulants and heroin with regard to attention, memory and executive functions

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

The psychotomimetic states inventory (PSI): measuring psychotic-type experiences from ketamine and cannabis.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Attention and mismatch negativity

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

The assessment and analysis of handedness: The Edinburgh inventory

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Glutamate receptor dysfunction and schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

NMDA receptor hypofunction model of schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

The effects of a sub-anaesthetic dose of ketamine on human selective attention.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Rimonabant: a novel selective cannabinoid-1 receptor antagonist for treatment of obesity

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Memory-based comparison process not attenuated by haloperidol: a combined MEG and EEG study

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Psychiatric safety of ketamine in psychopharmacology research

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Modelling prefrontal cortex deficits in schizophrenia: implications for treatment

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

SR141716A, a potent and selective antagonist of the brain cannabinoid receptor

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Auditory mismatch negativity deficits in long-term heavy cannabis users.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Phencyclidine and glutamate agonist LY379268 stimulate dopamine D2High receptors: D2 basis for schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Dopamine D2High receptors stimulated by phencyclidines, lysergic acid diethylamide, salvinorin A, and modafinil

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measures

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Mismatch negativity in schizophrenia: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

How specific are deficits in mismatch negativity generation to schizophrenia?

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Electrophysiological indices of automatic and controlled auditory information processing in first-episode, recent-onset and chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Involvement of the endocannabinoid system in phencyclidine-induced cognitive deficits modelling schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Spatio-temporal source imaging reveals subcomponents of the human auditory mismatch negativity in the cingulum and right inferior temporal gyrus.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

What are the functional consequences of neurocognitive deficits in schizophrenia?

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21590281

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The mismatch negativity: a powerful tool for cognitive neuroscience

1 reference

https://pubmed.ncbi.nlm.nih.gov/21590281

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cannabinoids modulate synaptic strength and plasticity at glutamatergic synapses of rat prefrontal cortex pyramidal neurons.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21590281

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neurocognitive impairment in schizophrenia and how it affects treatment options

1 reference

https://pubmed.ncbi.nlm.nih.gov/21590281

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of ketamine in man

1 reference

https://pubmed.ncbi.nlm.nih.gov/21590281

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10

1 reference

https://pubmed.ncbi.nlm.nih.gov/21590281

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Guidelines for using human event-related potentials to study cognition: recording standards and publication criteria

1 reference

https://pubmed.ncbi.nlm.nih.gov/21590281

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cannabis and cognitive dysfunction: parallels with endophenotypes of schizophrenia?

1 reference

https://pubmed.ncbi.nlm.nih.gov/21590281

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21590281

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21590281

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The glutamate synapse in neuropsychiatric disorders. Focus on schizophrenia and Alzheimer's disease.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21590281

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Delta9-tetrahydrocannabinol acts as a partial agonist to modulate glutamatergic synaptic transmission between rat hippocampal neurons in culture.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21590281

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

SR 141716A acts as an inverse agonist to increase neuronal voltage-dependent Ca2+ currents by reversal of tonic CB1 cannabinoid receptor activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/21590281

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00213-011-2352-Y

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/21590281

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/21590281

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48262695&oldid=1786043322"